OverviewSuggest Edit

Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

... Show more
TypePublic
Founded1994
HQLexington, US
Websiteagenusbio.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Feb 2019)255
Job Openings30
Revenue (FY, 2017)$42.9 M(+90%)
Share Price (Feb 2019)$3.6

Key People/Management at Agenus

Garo Armen

Garo Armen

PhD, Chairman and CEO
Jennifer Buell

Jennifer Buell

PhD, Chief Operating Officer
Ozer Baysal

Ozer Baysal

Chief Commercial Officer and Head of Human Resources
Alex Duncan

Alex Duncan

PhD, Chief Technology Officer and Head of Research
Christian Cortis

Christian Cortis

PhD, Chief Strategy Officer & Head of Finance
Show more

Agenus Office Locations

Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Road
Berkeley, US
793 Heinz Ave
New York, US
149 Fifth Ave. Suite 500
Cambridge, GB
315 Science Park Milton Road
Show all (4)
Report incorrect company information

Agenus Financials and Metrics

Agenus Revenue

Agenus's revenue was reported to be $42.88 m in FY, 2017
USD

Revenue (Q3, 2018)

12.8m

Net income (Q3, 2018)

(33.7m)

EBIT (Q3, 2018)

(26.1m)

Market capitalization (15-Feb-2019)

473.3m

Closing stock price (15-Feb-2019)

3.6

Cash (30-Sep-2018)

46.2m

EV

440.3m
Agenus's current market capitalization is $473.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.0m7.0m24.8m22.6m42.9m

Revenue growth, %

129%256%(9%)

Cost of goods sold

536.1k

Gross profit

2.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

736.0k720.9k3.1m1.6m4.0m6.4m6.8m6.0m6.6m4.4m27.0m4.2m3.4m1.6m15.9m12.8m

General and administrative expense

3.6m5.2m5.8m4.9m5.5m8.0m6.4m9.2m7.1m8.1m7.8m8.1m8.1m8.9m9.5m9.2m

R&D expense

3.9m4.5m5.2m5.3m9.2m24.8m18.5m5.8m6.6m4.4m27.0m4.2m3.4m29.4m29.3m29.9m

Operating expense total

7.5m9.6m11.1m10.2m14.7m32.8m24.9m15.0m13.7m12.6m34.7m12.3m11.4m38.4m77.1m39.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

27.4m25.7m136.7m71.4m60.2m

Accounts Receivable

1.2k9.8m11.4m1.1m

Inventories

95.7k88.2k88.2k79.5k

Current Assets

28.2m42.7m184.1m91.3m73.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

30.2m73.5m48.3m38.4m79.3m124.7m184.1m78.3m73.4m75.4m113.9m81.8m65.1m52.3m43.2m46.2m

Accounts Receivable

1.1k2.5m4.1m7.3m10.2m9.4m10.3m6.8m3.9m2.2m1.1m10.9m6.1m

Inventories

3.3k95.7k95.7k88.2k88.2k88.2k88.2k88.2k88.2k87.5k87.0k80.2k62.2k55.5k55.5k

Current Assets

30.9m75.3m67.0m55.2m85.2m146.3m208.9m161.6m136.1m109.5m138.0m110.7m84.3m65.2m67.7m67.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.1m)(42.5m)(87.9m)(127.0m)(120.7m)

Depreciation and Amortization

586.3k1.6m2.0m4.9m6.0m

Inventories

16.0k(95.7k)7.5k7.5k8.7k

Accounts Payable

189.6k(45.9k)2.7m419.7k1.6m
USDY, 2018

EV/EBIT

-16.9 x

EV/CFO

-4.6 x

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-1 x
Show all financial metrics
Report incorrect company information

Agenus Online and Social Media Presence

Embed Graph
Report incorrect company information

Agenus News and Updates

Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

LEXINGTON, Mass., Feb. 15, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that its Biotech Electronic Security Token (BEST), the...

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead...

Agenus Awarded Grant to Enable QS-21 Innovations

LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill & Melinda Gates Foundation awarded it a grant ...

Thinking about buying stock in Agenus Inc., BlackBerry Limited, Caesars Entertainment Corp., New Age Beverages Corp., or Twitter, Inc.?

NEW YORK, Dec. 21, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGEN, BB, CZR, NBEV, and TWTR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Agenus stock shoots up 60% after announcing drug development deal with Gilead

Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and …

Gilead, Agenus sign deal to develop immuno-oncology therapieswdxefcqufszuzezftuxetqsqxt

Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.
Show more
Report incorrect company information

Agenus Blogs

Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

- The Biotech Electronic Security Token (BEST) is designed to be an innovative and transformative way to finance drug development through increasing liquidity, minimizing dilution, and improving capital allocation

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- Cash milestones earned from Merck & Incyte

Agenus Company Life and Culture

Report incorrect company information

Agenus Frequently Asked Questions

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Who are Agenus key executives?

    Agenus's key executives are Garo Armen, Jennifer Buell and Ozer Baysal.

  • How many employees does Agenus have?

    Agenus has 255 employees.

  • What is Agenus revenue?

    Latest Agenus annual revenue is $42.9 m.

  • What is Agenus revenue per employee?

    Latest Agenus revenue per employee is $168.1 k.

  • Who are Agenus competitors?

    Competitors of Agenus include LogicBio Therapeutics, NextCure and ImmunoCellular Therapeutics.

  • Where is Agenus headquarters?

    Agenus headquarters is located at 3 Forbes Road , Lexington.

  • Where are Agenus offices?

    Agenus has offices in Lexington, Berkeley, New York and Cambridge.

  • How many offices does Agenus have?

    Agenus has 4 offices.